roztwór do infuzji
Sponsors
Pharmacosmos A/S, Medical University Of Lodz, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Uniwersytet Jagiellonski Collegium Medicum, Medical University Of Gdansk
Conditions
Acute Myeloid LeucaemiaAcute Myeloid LeukemiaAcute ischemic strokeAcute myeloid leukemiaDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCLDiffuse large B-cell lymphomas (DLBCLExtensive Stage Small Cell Lung CancerFrailty with Iron Deficiency in Elderly Patients with Cardiovascular Disease
Phase 1
Phase 2
A phase II study of preoperative stereotactic radiation therapy boost combined with short-course immunotherapy (pembrolizumab versus placebo, randomized, double-blind) and standard chemotherapy in patients with newly diagnosed HER2-negative non-metastatic breast cancer with lack of early metabolic response in 18-fluorodeoxyglucoseFDG-PET/CT after 1st chemoterapy cycle
RecruitingCTIS2023-504145-31-00
Start: 2024-06-10Target: 78Updated: 2024-02-21
Assessment of Tolerance and Effectiveness of Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Active, not recruitingCTIS2024-517477-24-00
Start: 2022-02-17Target: 40Updated: 2025-04-02
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
Not yet recruitingCTIS2024-518275-64-00
Target: 340Updated: 2025-11-24
A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with the specific antidote
RecruitingCTIS2024-518509-17-00
Start: 2022-01-10Target: 300Updated: 2024-12-09
CLASP MS: The study evaluating the efficacy and safety of Polish cladribine in the treatment of patients with secondary progressive multiple sclerosis - a phase 2, randomized, double-blind, placebo-controlled trial.
Not yet recruitingCTIS2024-516992-33-02
Target: 188Updated: 2025-01-30
Comparison of treatment efficacy in the patients with Systemic sclerOsis: dapagliFlozin vs. Tocilizumab – a randomized head to head study
WithdrawnCTIS2025-523714-92-00
Target: 80Updated: 2025-12-15
Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy
RecruitingCTIS2022-502357-34-00
Start: 2023-09-27Target: 250Updated: 2025-12-18
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
RecruitingCTIS2023-503394-37-00
Start: 2024-10-23Target: 520Updated: 2025-10-15
The effect of noradrenaline infusion versus standard blood pressure management on perioperative HYPotension in NOncaRdiac surgery.
RecruitingCTIS2023-508255-39-00
Start: 2025-06-16Target: 750Updated: 2025-12-17
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial)
CompletedCTIS2024-515060-32-00
Start: 2024-11-22End: 2025-12-22Target: 190Updated: 2025-12-14
Phase 4
Effect of intravenous ferric carboxymaltose on mortality and cardiovascular morbidity, and quality of life in iron deficient patients with recent myocardial infarction
RecruitingCTIS2024-517206-28-00
Start: 2022-09-21Target: 1000Updated: 2024-11-18
A randomised, double-blind, three parallel-group, placebo controlled superiority trial assessing the effect of intravenous versus oral iron supplementation on physical performance, quality of life and cognitive function in iron deficient FRAIL elderly IndiviDuals with cardiovascular disease (FRAIL-ID trial)
Not yet recruitingCTIS2025-521570-34-00
Target: 396Updated: 2026-06-05